UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Cancer, 2019-08, Vol.125 (15), p.2561-2569

2019

Volltextzugriff (PDF)

Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 (177Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.477-e895

2020

Volltextzugriff (PDF)

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Molecular cancer therapeutics, 2018-09, Vol.17 (9), p.1927-1940

2018

Volltextzugriff (PDF)

Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment

Molecular cancer research, 2016-11, Vol.14 (11), p.1045-1053

2016

Volltextzugriff (PDF)

Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Urologic oncology, 2020-11, Vol.38 (11), p.848.e9-848.e16

2020

Volltextzugriff (PDF)

Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

Translational andrology and urology, 2019-07, Vol.8 (Suppl 3), p.S263-S264

2019

Volltextzugriff (PDF)

MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177 LU-J591) FOR MCRPC

The Journal of urology, 2016-04, Vol.195 (4), p.e680-e680

2016

Volltextzugriff (PDF)

Abstract P3-04-01: Information availability about screening for high-risk breast cancer on cancer center websites

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P3-P3-04-01

2022

Volltextzugriff (PDF)

MP80-04 89ZR-DF-IAB2M AND 68GA-PSMA-11 IMAGING IN LOCALIZED PRE-PROSTATECTOMY PROSTATE CANCER PATIENTS

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Volltextzugriff (PDF)

Abstract 5201: PSMA-targeted alpha radioimmunotherapy for prostate cancer with 225Ac-J591

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5201-5201

2017

Volltextzugriff (PDF)

Epidemiology of Heart Failure with Preserved Ejection Fraction

Current heart failure reports, 2014-12, Vol.11 (4), p.354-365

2014

Volltextzugriff (PDF)

Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow

Cancer research (Chicago, Ill.), 2013-10, Vol.73 (20), p.6111-6117

2013

Volltextzugriff (PDF)

Phase I dose-escalation study of fractionated-dose 177 Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS5093-TPS5093

2017

Volltextzugriff (PDF)

Abstract CT306: Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT306-CT306

2015

Volltextzugriff (PDF)

Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3971-3971

2016

Volltextzugriff (PDF)

Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT140-CT140

2016

Volltextzugriff (PDF)

Final results of 2-dose fractionation of 177 Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5022-5022

2016

Volltextzugriff (PDF)

Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.199-199

2015

Volltextzugriff (PDF)

Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy ( 177 Lu−J591) for progressive metastatic castration−resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.205-205

2016

Volltextzugriff (PDF)

Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy ( 177 Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.194-194

2015

Volltextzugriff (PDF)

A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential

Journal of biomarkers, 2014-01, Vol.2014 (2014), p.1-12

2014

Volltextzugriff (PDF)

Uncommon Cancers of the Prostate

Textbook of Uncommon Cancer, 2017, p.68-96

2017

Volltextzugriff (PDF)

Inland cholera in freshwater environs of north India

Vaccine, 2020-02, Vol.38, p.A63-A72

2020

Volltextzugriff (PDF)

Cluster ad hoc network topology control: Protocol and algorithm

AIP Conference Proceedings, 2022, Vol.2451 (1)

2022

Volltextzugriff (PDF)

Prediction of tensile behavior of FS welded AA7039 using machine learning

Materials today communications, 2021-03, Vol.26, p.101933, Article 101933

2021

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(10)
Humans
(7)
Oncology
(6)
Animals
(3)
Male
(3)
Prostate Cancer
(3)
Antigens, Surface - Immunology
(2)
Biological And Medical Sciences
(2)
Cell Line, Tumor
(2)
Epidemiology
(2)
Glutamate Carboxypeptidase Ii - Immunology
(2)
Medical Sciences
(2)
Mice
(2)
Pharmacology. Drug Treatments
(2)
Prostate-Specific Membrane Antigen
(2)
Radioimmunotherapy
(2)
Survival Analysis
(2)
Tumors
(2)
Urology & Nephrology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 (177Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment

Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177 LU-J591) FOR MCRPC

Abstract P3-04-01: Information availability about screening for high-risk breast cancer on cancer center websites

MP80-04 89ZR-DF-IAB2M AND 68GA-PSMA-11 IMAGING IN LOCALIZED PRE-PROSTATECTOMY PROSTATE CANCER PATIENTS

Abstract 5201: PSMA-targeted alpha radioimmunotherapy for prostate cancer with 225Ac-J591

Epidemiology of Heart Failure with Preserved Ejection Fraction

Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow

Phase I dose-escalation study of fractionated-dose 177 Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Abstract CT306: Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer

Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)

Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)

Final results of 2-dose fractionation of 177 Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC)

Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count

Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy ( 177 Lu−J591) for progressive metastatic castration−resistant prostate cancer (mCRPC)

Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy ( 177 Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC)

A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential

Uncommon Cancers of the Prostate

Inland cholera in freshwater environs of north India

Cluster ad hoc network topology control: Protocol and algorithm

Prediction of tensile behavior of FS welded AA7039 using machine learning

Suchergebnisse filtern